Nivolumab (NIVO) plus chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/ gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4year (y) follow-up (FU) of CheckMate 649

被引：0
|
作者：
Wyrwicz, L. S. [1 ]
Shitara, K. [2 ]
Moehler, M. [3 ]
Ajani, J. A. [4 ]
Shen, L. [5 ]
Garrido, M. [6 ]
Gallardo Araneda, C. E. [7 ]
Yamaguchi, K. [8 ]
Cleary, J. [9 ]
Elimova, E. [10 ]
Bruges Maya, R. [11 ]
Karamouzis, M. V. [12 ]
Skoczylas, T. [13 ]
Bragagnoli, A. C. [14 ]
Liu, T. [15 ]
Tehfe, M. [16 ]
Feeney, K. [17 ,18 ]
Wang, R. [19 ]
Zhang, J. [20 ]
Janjigian, Y. Y. [21 ,22 ]
机构：
[1] Narodowy Instytut Onkol, Dept Radiotherapy & Oncol, Klin Onkol & Radioterapii, Warsaw, Poland
[2] Natl Canc Ctr Hosp East, Dept Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[3] Johannes Gutenberg Univ Clin, Dept Med, Mainz, Germany
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX USA
[5] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res Minist Educ, Dept Gastrointestinal Oncol, Beijing, Peoples R China
[6] Pontificia Univ Catolica, Hematooncol Dept, Clin San Carlos de Apoquindo, Santiago, Chile
[7] Fdn Arturo Lopez Perez, Dept Med Oncol, Providencia, Chile
[8] Canc Inst Hosp JFCR, Gastroenterol Chemotherapy Dept, Koto Ku, Tokyo, Japan
[9] Dana Farber Canc Inst, Med Oncol, Boston, MA USA
[10] Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada
[11] Inst Nacl Cancerol ESE, Oncol Clin, Bogota, Colombia
[12] Laiko Gen Hosp Athens, Dept Biol Chem, Athens, Greece
[13] Med Univ Lublin, Dept Gen Surg, Klin Chirurg Ogolnej Gastroenterologicznej & No 2, Lublin, Poland
[14] Fundacao Pio Xii Hosp Canc Barretos, GI Canc, Barretos, Brazil
[15] Fudan Univ, Zhongshan Hosp, Oncol Dept, Shanghai, Peoples R China
[16] Ctr Hosp Univ Montreal, Oncol Ctr, Hematooncol Dept, Montreal, PQ, Canada
[17] Notre Dame Univ, Dept Canc Serv, Murdoch, WA, Australia
[18] Edith Cowan Univ, Murdoch, WA, Australia
[19] Bristol Myers Squibb, Oncol Precis Med, Princeton, NJ USA
[20] Bristol Myers Squibb, Oncol Clin Dev, Princeton, NJ USA
[21] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY USA
[22] Weill Cornell Med Coll, New York, NY USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.333
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
419P
引用
收藏
页码：S169 / S170
页数：2
相关论文
共 50 条
  • [41] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648.
    Chau, Ian
    Ajani, Jaffer A.
    Doki, Yuichiro
    Xu, Jianming
    Wyrwicz, Lucjan
    Motoyama, Satoru
    Ogata, Takashi
    Kawakami, Hisato
    Hsu, Chih-Hung
    Adenis, Antoine
    El Hajbi, Farid
    Di Bartolomeo, Maria
    Braghiroli, Maria Ignez Freitas Melro
    Holtved, Eva
    Murphy, Mariela A. Blum
    Abdullaev, Sandzhar
    Soleymani, Samira
    Lei, Ming
    Kato, Ken
    Kitagawa, Yuko
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [42] Rationale 305: Phase 3 study of tislelizumab plus chemotherapy vs placebo plus chemotherapy as first-line treatment (1L) of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC).
    Moehler, Markus H.
    Kato, Ken
    Arkenau, Hendrik-Tobias
    Oh, Do-Youn
    Tabernero, Josep
    Cruz-Correa, Marcia
    Wang, HongWei
    Xu, Hui
    Li, Jiang
    Yang, Silu
    Xu, Rui-hua
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 286 - 286
  • [43] Nivolumab (NIVO) plus chemotherapy (chemo) or ipilimumab (IPI) vs chemo as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): Expanded efficacy and safety analyses from CheckMate 648
    Chau, I.
    Ajani, J.
    Doki, Y.
    Xu, J.
    Wyrwicz, L.
    Motoyama, S.
    Ogata, T.
    Kawakami, H.
    Hsu, C.
    Adenis, A.
    El Hajbi, F.
    Di Bartolomeo, M.
    Braghiroli, M.
    Holtved, E.
    Murphy, M. Blum
    Abdullaev, S.
    Soleymani, S.
    Lei, M.
    Kato, K.
    Kitagawa, Y.
    ANNALS OF ONCOLOGY, 2022, 33 : S379 - S380
  • [44] Health-related quality of life (HRQOL) in patients with advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma cancer (GC/GEJC/EAC): 36-month results of CheckMate 649 nivolumab plus chemotherapy (N plus C) vs (C)
    Moehler, Markus
    Wyrwicz, Lucjan
    Chen, Clara
    Davenport, Eric
    Wang, Jinyi
    Nathani, Raheel
    Kondo, Kaoru
    Elimova, Elena
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 65 - 65
  • [45] TREATMENT PATTERNS AND PERFORMANCE STATUS IN UNRESECTABLE ADVANCED OR METASTATIC (ADV/MET) GASTRIC CANCER (GC), GASTROESOPHAGEAL JUNCTION CANCER (GEJC) AND ESOPHAGEAL ADENOCARCINOMA (EAC) PATIENTS RECEIVING FIRST LINE (1L) TREATMENT
    Hall, J.
    Khela, K.
    Middleton-Dalby, C.
    Bertwistle, D.
    Xiao, H.
    VALUE IN HEALTH, 2020, 23 : S485 - S485
  • [46] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649
    Moehler, M.
    Elimova, E.
    Blum, S., I
    Xiao, H.
    Davenport, E.
    Wang, J.
    Hunter, S.
    Li, M.
    Kondo, K.
    Wyrwicz, L.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 214 - 215
  • [47] Tislelizumab (TIS) plus chemotherapy (Chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment of advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJC): Health-related quality of life (HRQoL) outcomes in the RATIONALE-305 study.
    Cruz-Correa, Marcia
    Xu, Rui-Hua
    Moehler, Markus H.
    Oh, Do-Youn
    Kato, Ken
    Spigel, David R.
    Arkenau, Hendrik-Tobias
    Tabernero, Josep
    Zimina, Anastasia V.
    Bai, Yuxian
    Shi, Jianhua
    Lee, Keun-Wook
    Hirano, Hidekazu
    Wyrwicz, Lucjan S.
    Pazo Cid, Roberto
    Xu, Hui
    Sheng, Tao
    Barnes, Gisoo
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 290 - 290
  • [48] Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N plus C) versus (C) from CheckMate 649.
    Wyrwicz, Lucjan
    Elimova, Elena
    Blum, Steven I.
    Xiao, Hong
    Davenport, Eric
    Wang, Jinyi
    Hunter, Shannon
    Li, Mingshun
    Kondo, Kaoru
    Moehler, Markus H.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [49] Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.
    Paz-Ares, Luis G.
    Ciuleanu, Tudor-Eliade
    Lee, Jong-Seok
    Urban, Laszlo
    Caro, Reyes Bernabe
    Park, Keunchil
    Sakai, Hiroshi
    Ohe, Yuichiro
    Nishio, Makoto
    Pluzanski, Adam
    Ramalingam, Suresh S.
    Brahmer, Julie R.
    Borghaei, Hossein
    O'Byrne, Kenneth John
    Hellmann, Matthew D.
    Memaj, Arteid
    Bushong, Judith
    Tran, Phuong
    Reck, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [50] First-line pembrolizumab (pembro) plus chemotherapy (chemo) for advanced gastroesophageal junction cancer (GEJC) and esophageal adenocarcinoma (EAC): Analysis of KEYNOTE-590 and KEYNOTE-859 by tumor type.
    Shiu, Kai-Keen
    Rivera, Fernando
    Medley, Louise C.
    Aghmesheh, Morteza
    Dunne, Richard Francis
    Roy, Rajarshi
    Wyrwicz, Lucjan S.
    Larson, Timothy
    Metges, Jean-Philippe
    Mansoor, Wasat
    Goekkurt, Eray
    Moreira Antunes, Luiz Carlos
    Castro Oliden, Victor
    Jensen, Erin
    Shah, Sukrut
    Bordia, Sonal
    Bhagia, Pooja
    Lowery, Maeve Aine
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 345 - 345
12345